Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 February 2023 | Story Edzani Nephalela | Photo Edzani Nephalela
Dr Luyanda Marhaya
Dr Luyanda Marhaya, Director of Academic Planning and Quality Assurance at the UFS.

Dr Luyanda Marhaya, Director of Academic Planning and Quality Assurance at the University of the Free State (UFS), has been selected by the Department of Higher Education and Training (DHET) to join the Foundation Provision Reference Group (FPRG). His primary role in this position is to assist the Department in assessing applications for foundation programmes submitted by universities, ensuring compliance with the current Foundation Provision Guidelines. 

As the author of the book Does Extended Programme Provision Work in South Africa?, Dr Marhaya is a recognised expert in the field. 

The Department of Communication and Marketing (DCM) at the UFS recently interviewed Dr Marhaya to understand his responsibilities better:

Can you tell us more about your appointment as a member of the FPRG?

Over and above the supportive role, one of the major issues I will be involved in will be to provide input into the revision and finalisation of the Extended Curriculum Programme Policy Framework for the higher sector in South Africa.

What kind of projects or initiatives do you see being a priority?

One of the significant ongoing projects will be evaluating applications for foundation programmes of the different universities in South Africa, so one will have to allocate time, as many universities currently offer these programmes.

What do you hope to bring to the table as a group member?

Interestingly, I started as an academic about 15 years ago in the foundation programmes. I spent a good five years of my teaching at a university level dealing with students who gained entry through foundation programmes. I completely understand their purpose, intentions, and significance, especially concerning student access and success. 

How will the Foundation Provision Reference Group benefit students and the education system?

Student access is a serious issue in South Africa, especially regarding the preparedness of many university students. So, I believe if we develop guidelines that can assist universities in coordinating these programmes in a well-structured manner, there could be many benefits.

What challenges do you anticipate facing in this role, and how do you plan to address them?

I think the major issue will be time constraints. My role is very demanding, and I am already involved in several other external committees, such as the Council on Higher Education, so I think my time management has to be very good.

How do you plan to work with other group members to achieve the group’s goals?

I believe in lifelong learning. I will certainly contribute, but the value of these interactions comes from learning from others.

Can you discuss any past experiences that have prepared you for this role?

I also wrote a book, titled Does Extended Programme Provision Work in South Africa?, in which I explored all the intricacies around these programmes. As Director: Academic Planning at the UFS, I also oversee the quality and provision of foundation programmes, so you could say I bring some expertise.

What are your long-term goals for the foundation programmes, and your role as a reference group member?

I foresee this as a long-term service that will benefit the country as a whole, so I suppose the Department will keep up so that we can provide capacity development to all universities that offer foundation programmes.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept